Ronald Sugar - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Dr. Ronald D. Sugar, Ph.D., is an Independent Director of Amgen Inc. Ronald D. Sugar is the retired Chairman of the Board and Chief Executive Officer of Northrop Grumman Corporationrationration, a global aerospace and defense company, having held these posts from 2003 through 2009. Dr. Sugar was a director of Chevron Corporationrationration, a petroleum, exploration, production and refining company, since 2005, serving as the lead director and on the Management Compensation Committee and chairing the Board Nominating and Governance Committee Apple Inc., a manufacturer and seller of, among other things, personal computers, mobile communication and media devices, since 2010, chairing the Audit and Finance Committee and of Air Lease Corporationrationration, an aircraft leasing company, since 2010, chairing the Compensation Committee and serving on the Governance Committee. Since 2010, he was a senior advisor to Ares Management LLC, a privatelyheld asset manager and registered investment advisor. In 2014, Dr. Sugar joined the Temasek Americas Advisory Panel of Temasek Holdings Limited, a privatelyheld investment company based in Singapore
Age: 68  Director Since 2010      
805-447-1000  http://www.amgen.com
Sugar is a member of the National Academy of Engineering, trustee of the University of Southern California, member of the UCLA Anderson School of Management Board of Advisors, director of the Los Angeles Philharmonic Association and national trustee of the Boys and Girls Clubs of America.

Ronald Sugar Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Louis DrapeauBio Rad Laboratories
2007
Virgil ThompsonMallinckrodt Public Limited Com
2014
Robert BertoliniBristol Myers Squibb Company
2017
Juan LucianoEli Lilly and Company
2016
Carolyn BertozziEli Lilly and Company
2017
Christopher BodineAllergan plc
2013
David HooverEli Lilly and Company
2009
James BloemAllergan plc
2013
Thomas LynchBristol Myers Squibb Company
2017
Jackson TaiEli Lilly and Company
2013
Michelle KumbierAbbott Laboratories
2018
Carol DavidsonAllergan plc
2018
Jill SmithEndo International plc
N/A
Peter McDonnellAllergan plc
2015
Laurie GlimcherBristol Myers Squibb Company
N/A
Togo WestBristol Myers Squibb Company
2015
Raul AlvarezEli Lilly and Company
2009
Marschall RungeEli Lilly and Company
2013
Lewis CampbellBristol Myers Squibb Company
2014
Carlos RepresasMerck Co
2009
Jamere JacksonEli Lilly and Company
2016

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Did you try this?

Run Correlation Analysis Now
   

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Correlation Analysis

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.